Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel

Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune for new molecular entities with priority review status in the last year, the consulting firm Parexel concludes in a new report